IN8BIO Inc., a clinical-stage biopharmaceutical company, announced that its INB-200 clinical trial for glioblastoma patients has demonstrated significant clinical progress. A patient in the trial has surpassed four years without progression, marking a notable milestone in the treatment of front-line, grade IV glioblastoma. The company presented these positive results at the ASCO 2025 Annual Meeting, where it was reported that patients receiving multiple doses of INB-200 achieved a median progression-free survival of 16.1 months, notably longer than the 6.9 months typically observed with the standard-of-care Stupp protocol. Additionally, 40% of these patients remained progression-free for over 18 months with no significant toxicities observed. These findings highlight the potential of INB-200 to extend overall survival and provide durable therapy for glioblastoma patients.